Hospital Pharmacy - May 2017 - 346

346

6.

7.

8.

9.

10.

11.

12.

13.

14.

15.

16.
17.

18.

19.

20.

Hospital Pharmacy 52(5)
bevacizumab or single-agent bevacizumab as maintenance
therapy in patients with metastatic colorectal cancer: the phase
III MACRO TTD study. Oncologist. 2012;17(1):15-25.
Jackson CG, Sharples K, Thompson PI, et al. Dose-intense
capecitabine, oxaliplatin and bevacizumab as first line treatment for metastatic, unresectable colorectal cancer: a multicentre phase II study. BMC Cancer. 2014;14:737.
Vamvakas L, Matikas A, Karampezis A, et al. Capecitabine in
combination with oxaliplatin and bevacizumab (AXELOX) as
1st line treatment for fit and vulnerable elderly patients (aged
>70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group
(HORG). BMC Cancer. 2014;14:277.
Wong NS, Fernando NH, Bendell JC, et al. A phase II study
of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin
Colorectal Cancer. 2011;10(3):210-216.
Snoeren N, Voest EE, Bergman AM, et al. A randomized two
arm phase III study in patients post radical resection of liver
metastases of colorectal cancer to investigate bevacizumab in
combination with capecitabine plus oxaliplatin (CapOx) vs
CapOx alone as adjuvant treatment. BMC Cancer. 2010;10:545.
Gulhati P, Raghav K, Shroff RT, et al. Bevacizumab combined with capecitabine and oxaliplatin in patients with
advanced adenocarcinoma of the small bowel or ampulla of
Vater: a single-center, open-label, phase 2 study. Cancer.
2016;123(6):1011-1017.
doi:10.1002/cncr.30445.
http://
onlinelibrary.wiley.com/doi/10.1002/cncr.30445/pdf.
Accessed June 7, 2017.
National Cancer Comprehensive Network. NCCN clinical
practice guidelines-colon cancer. Version 2.2017. http://
www.nccn.org. Accessed February 2017.
National Cancer Comprehensive Network. NCCN clinical
practice guidelines-rectal cancer. Version 2.2017. http://
www.nccn.org. Accessed February 2017.
Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin
Oncol. 1997;15(1):103-109.
National Comprehensive Cancer Network. NCCN clinical
practice guidelines-antiemesis. V.2.2016. http://www.nccn.
org/professionals/physician_gls/pdf/antiemesis.pdf. Accessed
February 2017.
Hesketh PJ, Bohlke K, Lyman GH, et al. Antiemetics: American
Society of Clinical Oncology focused guideline update. J Clin
Oncol. 2016;34(4):381-386.
Multinational Association for Supportive Care in Cancer.
Antiemetic guidelines. 2016. Version.1.2. Accessed February 2017.
Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation
of clinical evidence and drug cost implications. J Clin Oncol.
2005;23(6):1289-1294.
Terrey JP, Aapro MS. The activity of granisetron in patients
who had previously failed ondansetron antiemetic therapy. Eur
J Clin Res. 1996;8:281-288.
Carmichael J, Keizer HJ, Cupissol D, et al. Use of granisetron
in patients refractory to previous treatment with antiemetics.
Anticancer Drugs. 1998;9(5):381-385.
de Wit R, de Boer AC, vd Linden GH, et al. Effective crossover to granisetron after failure to ondansetron, a randomized

21.

22.

23.

24.

25.

26.

27.

28.

29.

30.

31.

32.

33.

34.

double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001;85(8):1099-1101.
Smith IE. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy.
The Granisetron Study Group. J Cancer Res Clin Oncol.
1993;119(6):350-354.
Soukop M. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Granisetron
Study Group. Support Care Cancer. 1994;2(3):177-183.
Brandi G, Pantaleo MA, Galli C, et al. Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer. 2003;89(3):
477-481.
Dold F, Hoey D, Carbery M, et al. Hypersensitivity in patients
with metastatic colorectal carcinoma undergoing chemotherapy with oxaliplatin. Proc Am Soc Clin Oncol. 2002;21:1478.
Qureshi KM, Leichman C, Berdzik J et al. Incidence of hypersensitivity reactions to oxaliplatin (OXP) at Roswell Park
Cancer Institute (RPCI) and protocol for desensitization. Proc
Am Soc Clin Oncol. 2003;22:789.
Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update
of recommendations for the use of white blood cell growth
factors: an evidence-based clinical practice guideline. J Clin
Oncol. 2006;24(19):3187-3205.
National Comprehensive Cancer Network (NCCN). Clinical
practice guidelines in oncology-myeloid growth factors.
Version.2.2013. http://www.nccn.org/professionals/physician_
gls/pdf/myeloid_growth.pdf. Accessed February 2017.
Maroun JA, Anthony LB, Blais N, et al. Prevention and management of chemotherapy-induced diarrhea in patients with
colorectal cancer: a consensus statement by the Canadian
Working Group on chemotherapy-induced diarrhea. Curr
Oncol. 2007;14(1):13-20.
Benson AB, Ajani JA, Catalano RB, et al. Recommended
guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22(14):2918-2926.
Gamelin E, Gamelin L, Bossi L, et al. Clinical aspects and
molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol.
2002;29(suppl 15):21-33.
Otsuji T, Matsuoka M, Saraya Y, et al. Efficacy of calcium
and magnesium infusions for oxaliplatin-related neurotoxicity [abstract 393]. Proc Am Soc Clin Oncol. 2007. http://www.
asco.org/ASCOv2/Meetings/Abstracts?&;vmview=abst_
detail_view&confID=45&abstractID=10308.
Accessed
February 2017.
Grothey G, Nikcevich DA, Sloan JA, et al. Evaluation of the
effect of intravenous calcium and magnesium (CaMg) on
chronic and acute neurotoxicity associated with oxaliplatin:
results from a placebo-controlled phase III trial [abstract 4025].
Proc Am Soc Clin Oncol. 2009. http://www.asco.org/ASCOv2/
Meetings/Abstracts?&vmview=abst_detail_view&confID=65
&abstractID=33721. Accessed February 2017.
Grothey A, Nikcevich DA, Sloan JA, et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin
Oncol. 2011;29(4):421-427.
Loprinzi CL, Qin R, Dakhil SR, et al. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced


http://onlinelibrary.wiley.com/doi/10.1002/cncr.30445/pdf http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf http://onlinelibrary.wiley.com/doi/10.1002/cncr.30445/pdf http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf http://www.nccn.org http://www.nccn.org http://www.nccn.org http://www.nccn.org http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf http://www.nccn.org/professionals/physician_gls/pdf/antiemesis.pdf http://www.asco.org/ASCOv2/Meetings/Abstracts?&;vmview=abst_detail_view&confID=45&abstractID=10308 http://www.asco.org/ASCOv2/Meetings/Abstracts?&;vmview=abst_detail_view&confID=45&abstractID=10308 http://www.asco.org/ASCOv2/Meetings/Abstracts?&;vmview=abst_detail_view&confID=45&abstractID=10308 http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33721 http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33721 http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=33721

Table of Contents for the Digital Edition of Hospital Pharmacy - May 2017

Editorial, For Sale: FDA Priority Review Vouchers
Current FDA-Related Drug Information; Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals
Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings
ISMP Adverse Drug Reactions: Levofloxacin-Induced Neuroexcitation and Hallucinations Statin-Induced Muscle Rupture Mefloquine-Induced Rhabdomyolysis Methimazole-Induced
Critical Care Pharmacist Market Perceptions: Comparison of Critical Care Program Directors and Directors of Pharmacy
Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer
Clinical Pharmacy Discharge Counseling Service and the Impact on Readmission Rates in High-Risk Patients
Mannitol Prescribing Practices With Cisplatin Before and After an Educational Newsletter Intervention
Pharmacists’ Knowledge of the Cost of Laboratory Testing
Adverse Drug Reaction Reporting Practices Among United Arab Emirates Pharmacists and Prescribers
Postoperative Pain Management With Liposomal Bupivacaine in Patients Undergoing Orthopedic Knee and Hip Arthroplasty at a Community Hospital
Formulary Drug Reviews
Hospital Pharmacy - May 2017 - 317
Hospital Pharmacy - May 2017 - 318
Hospital Pharmacy - May 2017 - 319
Hospital Pharmacy - May 2017 - 320
Hospital Pharmacy - May 2017 - 321
Hospital Pharmacy - May 2017 - 322
Hospital Pharmacy - May 2017 - 323
Hospital Pharmacy - May 2017 - Editorial, For Sale: FDA Priority Review Vouchers
Hospital Pharmacy - May 2017 - 325
Hospital Pharmacy - May 2017 - Current FDA-Related Drug Information; Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals
Hospital Pharmacy - May 2017 - Summaries of Safety Labeling Changes Approved by the FDA: Boxed Warnings
Hospital Pharmacy - May 2017 - 328
Hospital Pharmacy - May 2017 - 329
Hospital Pharmacy - May 2017 - ISMP Adverse Drug Reactions: Levofloxacin-Induced Neuroexcitation and Hallucinations Statin-Induced Muscle Rupture Mefloquine-Induced Rhabdomyolysis Methimazole-Induced
Hospital Pharmacy - May 2017 - 331
Hospital Pharmacy - May 2017 - 332
Hospital Pharmacy - May 2017 - 333
Hospital Pharmacy - May 2017 - Critical Care Pharmacist Market Perceptions: Comparison of Critical Care Program Directors and Directors of Pharmacy
Hospital Pharmacy - May 2017 - 335
Hospital Pharmacy - May 2017 - 336
Hospital Pharmacy - May 2017 - 337
Hospital Pharmacy - May 2017 - 338
Hospital Pharmacy - May 2017 - 339
Hospital Pharmacy - May 2017 - 340
Hospital Pharmacy - May 2017 - Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer
Hospital Pharmacy - May 2017 - 342
Hospital Pharmacy - May 2017 - 343
Hospital Pharmacy - May 2017 - 344
Hospital Pharmacy - May 2017 - 345
Hospital Pharmacy - May 2017 - 346
Hospital Pharmacy - May 2017 - 347
Hospital Pharmacy - May 2017 - Clinical Pharmacy Discharge Counseling Service and the Impact on Readmission Rates in High-Risk Patients
Hospital Pharmacy - May 2017 - 349
Hospital Pharmacy - May 2017 - 350
Hospital Pharmacy - May 2017 - 351
Hospital Pharmacy - May 2017 - 352
Hospital Pharmacy - May 2017 - Mannitol Prescribing Practices With Cisplatin Before and After an Educational Newsletter Intervention
Hospital Pharmacy - May 2017 - 354
Hospital Pharmacy - May 2017 - 355
Hospital Pharmacy - May 2017 - 356
Hospital Pharmacy - May 2017 - Pharmacists’ Knowledge of the Cost of Laboratory Testing
Hospital Pharmacy - May 2017 - 358
Hospital Pharmacy - May 2017 - 359
Hospital Pharmacy - May 2017 - 360
Hospital Pharmacy - May 2017 - Adverse Drug Reaction Reporting Practices Among United Arab Emirates Pharmacists and Prescribers
Hospital Pharmacy - May 2017 - 362
Hospital Pharmacy - May 2017 - 363
Hospital Pharmacy - May 2017 - 364
Hospital Pharmacy - May 2017 - 365
Hospital Pharmacy - May 2017 - 366
Hospital Pharmacy - May 2017 - Postoperative Pain Management With Liposomal Bupivacaine in Patients Undergoing Orthopedic Knee and Hip Arthroplasty at a Community Hospital
Hospital Pharmacy - May 2017 - 368
Hospital Pharmacy - May 2017 - 369
Hospital Pharmacy - May 2017 - 370
Hospital Pharmacy - May 2017 - 371
Hospital Pharmacy - May 2017 - 372
Hospital Pharmacy - May 2017 - 373
Hospital Pharmacy - May 2017 - Formulary Drug Reviews
Hospital Pharmacy - May 2017 - 375
Hospital Pharmacy - May 2017 - 376
Hospital Pharmacy - May 2017 - 377
Hospital Pharmacy - May 2017 - 378
Hospital Pharmacy - May 2017 - 379
Hospital Pharmacy - May 2017 - 380
Hospital Pharmacy - May 2017 - 381
Hospital Pharmacy - May 2017 - 382
Hospital Pharmacy - May 2017 - 383
Hospital Pharmacy - May 2017 - 384
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2019
http://www.nxtbook.com/nxtbooks/sage/fai_201909
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_july2019
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2019
http://www.nxtbook.com/nxtbooks/sage/canadianpharmacistsjournal_05062019
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2019
http://www.nxtbook.com/nxtbooks/sage/sri_supplement_201903
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2019
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2018
http://www.nxtbook.com/nxtbooks/sage/tec_20180810
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2018
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_julyaugust2018
http://www.nxtbook.com/nxtbooks/sage/fai_201807
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2018
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_april2018
http://www.nxtbook.com/nxtbooks/sage/sri_supplement_201803
http://www.nxtbook.com/nxtbooks/sage/slas_discovery_201712
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_february2018
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_december2017
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_november2017
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_october2017
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_september2017
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_julyaugust2017
http://www.nxtbook.com/nxtbooks/sage/fai_supplement_201709
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_june2017
http://www.nxtbook.com/nxtbooks/sage/hospitalpharmacy_may2017
http://www.nxtbook.com/nxtbooks/sage/fai_201706
http://www.nxtbook.com/nxtbooks/sage/fai_201607
http://www.nxtbookMEDIA.com